A composition for treating wounds, methods and use thereof

Abstract

The present disclosure relates to a composition comprising a peptide having at least 90% sequence homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF). It also relates to a process of preparing the composition and its use in treating wounds, including diabetic wound complications.

Description

[0001] “A COMPOSITION FOR TREATING WOUNDS, METHODS AND USE THEREOF”

[0002] TECHNICAL FIELD

[0003] The present disclosure relates to the field of compositions and therapeutics. Particularly, the present disclosure relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF). It also relates to a process of preparing the composition and its use in treating wounds, including diabetic wound complications.

[0004] BACKGROUND AND PRIOR ART

[0005] Efficient wound healing is a major challenge and they are characterized by higher levels of inflammatory markers, decreased growth factor activity, reduced cellular proliferation, etc. Wounds can be categorized into diabetic wounds, ulcers such as pressure ulcers and venous leg ulcers, bedsore, burns, etc. Generally, impaired wound healing greatly impacts physical, psychological, social, and economic aspects for patients, affecting their quality of life.

[0006] In case of diabetic wounds, approximately 15-20% of all diabetes patients are expected to suffer from chronic ulcers / diabetic foot ulcers at some point in their lifetime. Currently, clinicians treat diabetic ulcers with local wound care including surgical debridement, treatment with antimicrobials and maintenance of a moist environment using dressings. If the wounds so not respond to this kind of local treatment, further treatment can include treatment with growth factors, hyperbaric oxygen therapy and negative pressure therapy. Recombinant human growth factors like Epidermal Growth Factor (EGF) and Fibroblast growth factor (FGF) can help treat diabetic ulcers by increasing the fibroblast proliferation at the wound site and by promoting re- epithelialization. Human epidermal growth factor gel has been approved in India for treatment of diabetic foot ulcers. However, this approach suffers from a few drawbacks. In diabetes patients, collagen deposition during wound healing is significantly impaired which leads to delayed wound healing. In addition, diabetes patients show chronic inflammation in the wound microenvironment which leads to cellular damage and an overall decrease in the rate of wound healing. Hence, there is a need for approaches which can lead to faster and more efficient wound healing and the present disclosure achieves this objective by providing a composition for treating wounds, including diabetic wound complications.

[0007] SUMMARY OF THE INVENTION

[0008] The present disclosure relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) optionally along with excipients. The present disclosure also relates to a process of preparing the composition and a method of treating wounds, said method comprising administering / applying an effective amount of a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 with epidermal growth factor (EGF) to a subject in need thereof.

[0009] BRIEF DESCRIPTION OF ACCOMPANYING FIGURES

[0010] Figure 1: Shows percent wound contraction in animals treated with EGF alone, peptide alone and a combination of EGF + peptide.

[0011] Figure 2: Shows images of wound contraction in animals treated with EGF alone, peptide alone and a combination of EGF + peptide.

[0012] Figure 3: Shows collagen content in skin of the animals treated with EGF alone, peptide alone and a combination of EGF + peptide.

[0013] Figure 4: Histological analysis of healed wounds in diabetic animals; Skin: {H & E staining, 100X} showing F: fibrous tissue proliferation, N: neovascularization and E: epithelialization.

[0014] DETAILED DESCRIPTION OF THE INVENTION

[0015] The foregoing has broadly outlined the features and technical advantages of the present disclosure in order that the detailed description of the disclosure that follows may be better understood. Additional features and advantages of the disclosure will be described hereinafter which form the subject of the description of the disclosure. It should also be realized by those skilled in the art that such equivalent product / methods do not depart from the scope of the disclosure.

[0016] Definitions:

[0017] Unless otherwise defined, all terms used in the disclosure, including technical and scientific terms, have meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0018] As used herein, the singular forms ‘a’, ‘an’ and ‘the’ include both singular and plural referents unless the context clearly dictates otherwise.

[0019] The term ‘comprising’, ‘comprises’ or ‘comprised of as used herein are synonymous with ‘including’, ‘includes’, ‘containing’ or ‘contains’ and are inclusive or open-ended and do not exclude additional, non-recited members, elements or method steps. Likewise, certain terms may be interchangeably used throughout the specification and thus have the same meaning even when they are referred interchangeably.

[0020] The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within the respective ranges, as well as the recited endpoints.

[0021] The term ‘about’ as used herein when referring to a measurable value such as a parameter, an amount, a temporal duration, and the like, is meant to encompass variations of ±10% or less, preferably ±5% or less, more preferably ±1% or less and still more preferably ±0.1% or less of and from the specified value, in so far such variations are appropriate to perform the present disclosure. It is to be understood that the value to which the modifier ‘about’ refers is itself also specifically, and preferably disclosed.

[0022] The present disclosure relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF). The composition is useful in treating wounds such as but not limited to diabetic wound, bedsore, pressure ulcers and burns. The treatment results in a reduced scar or no scar [scarless wound healing]. In an embodiment of the present disclosure, the composition comprises a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF).

[0023] In an embodiment of the present disclosure, the composition comprises a peptide having at least 95% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF).

[0024] In an embodiment of the present disclosure, the composition comprises a peptide having at least 96% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF).

[0025] In an embodiment of the present disclosure, the composition comprises a peptide having at least 97% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF).

[0026] In an embodiment of the present disclosure, the composition comprises a peptide having at least 98% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF).

[0027] In an embodiment of the present disclosure, the composition comprises a peptide having at least 99% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF).

[0028] In a preferred embodiment of the present disclosure, the composition comprises a peptide of SEQ ID No. 1 (KTLLEQTLALLPAALPLLAAPLAPLTLRRRRPKIKQ) and EGF.

[0029] In an embodiment of the present disclosure, concentration of the peptide is in the range of about 0.01% - 2% and concentration of EGF is in the range of about 0.01% - 2%.

[0030] In an embodiment of the present disclosure, concentration of the peptide is about 0.01%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 1.5% and about 2% or any other concentration within the range of about 0.01% - 2%.

[0031] In an embodiment of the present disclosure, concentration of the EGF is about 0.01%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 1.5% and about 2% or any other concentration within the range of about 0.01% - 2%. In an embodiment of the present disclosure, the composition optionally / further comprises excipients.

[0032] In an embodiment of the present disclosure, the excipients are in the range of about 94% - 99.98%

[0033] In an embodiment of the present disclosure, the excipients are at a concentration of about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about 99.90%, about 99.92%, about 99.94%, about 99.96% and about 99.98% or any other concentration within the range of 94% - 99.98%.

[0034] In an embodiment of the present disclosure, the excipients are selected from a group comprising but not limited to preservatives, buffering agents, stabilizers, binders, lubricants, compaction agents, disintegration agents, dispersion agents, coloring agents, additive, solvent, surfactant, anti-oxidant, suspending agent, emulsifying agent or combinations thereof.

[0035] In an embodiment of the present disclosure, the composition is administered through modes such as but not limiting to intranasal, intravenous, intraperitoneal, intramuscular, sub-cutaneous, cutaneous, intradermal, oral, topical, cosmetic or combinations thereof.

[0036] In an embodiment of the present invention, the composition is formulated into various forms selected from a group comprising but not limiting to drops, patches, nebulizers, injections, tablet, aerosols, atomized droplets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups, elixirs, cream, paste, spray, lotion, powder, ointment or combinations thereof.

[0037] In a preferred embodiment of the present disclosure, the composition is formulated into a topical / cosmetic composition. In a preferred embodiment of the present disclosure, the composition is formulated into forms selected from a group comprising gel, cream, paste, spray, lotion, powder, ointment or combinations thereof.

[0038] The present disclosure also relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 at a concentration ranging from about 0.01% - 2%, EGF at a concentration ranging from about 0.01% - 2% and excipients at a concentration ranging from about 94% - 99.98%.

[0039] The present disclosure also relates to a process of preparing the composition, said method comprising steps of combining a peptide having at least 90% homology to a peptide of SEQ ID No. 1 with epidermal growth factor (EGF).

[0040] In a preferred embodiment, the present disclosure relates to a process of preparing the composition, said method comprising steps of combining a peptide of SEQ ID No. 1 with epidermal growth factor 1 (EGF).

[0041] In an embodiment of the present disclosure, the peptide is synthesized before combining with epidermal growth factor (EGF).

[0042] In an embodiment of the present disclosure, concentration of the peptide is in the range of about 0.01% - 2% and the concentration of EGF is in the range of about 0.01% - 2%.

[0043] In an embodiment of the present disclosure, concentration of the peptide is about 0.01%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 1.5% and about 2% or any other concentration within the range of about 0.01% - 2%.

[0044] In an embodiment of the present disclosure, concentration of the EGF is about 0.01%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 1.5% and about 2% or any other concentration within the range of about 0.01% - 2%. In an embodiment of the present disclosure, the process optionally / further comprises inclusion of excipients in the composition.

[0045] In an embodiment of the present disclosure, the excipients are in the range of about 94% - 99.98%.

[0046] In an embodiment of the present disclosure, the excipients are at a concentration of about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about 99.90%, about 99.92%, about 99.94%, about 99.96% and about 99.98% or any other concentration within the range of 94% - 99.98%.

[0047] The present disclosure also relates to a method of treating wounds, said method comprising administering / applying an effective amount of a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) to a subject in need thereof.

[0048] In a preferred embodiment, the present disclosure relates to a method of treating wounds, said method comprising administering / applying an effective amount of a composition comprising a peptide of SEQ ID No. 1 and EGF to a subject in need thereof.

[0049] The present disclosure also relates to use of the composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No.l and epidermal growth factor (EGF) in manufacturing a medicament for treating wounds.

[0050] In a preferred embodiment, the present disclosure relates to use of the composition comprising peptide of SEQ ID No. 1 and epidermal growth factor (EGF) in manufacturing a medicament for treating wounds. The present disclosure also relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) for use in treating wounds.

[0051] The present disclosure also relates to a composition comprising a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) for use in treating wounds.

[0052] In an embodiment of the present disclosure, the wounds are such as but not limited to diabetic wound, bedsore, pressure ulcers and burns.

[0053] In an embodiment of the present disclosure, the method results in a reduced scar or no scar [scarless wound healing] .

[0054] The present disclosure also relates to a method of treating diabetic wound complication, said method comprising administering / applying an effective amount of a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) to a subject in need thereof.

[0055] In a preferred embodiment, the present disclosure relates to a method of treating diabetic wound complication, said method comprising administering / applying an effective amount of a composition comprising a peptide of SEQ ID No. 1 and EGF to a subject in need thereof.

[0056] The present disclosure also relates to use of the composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) in manufacturing a medicament for treating diabetic wound complication.

[0057] In a preferred embodiment, the present disclosure relates to use of the composition comprising a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) in manufacturing a medicament for treating diabetic wound complication. The present disclosure also relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) for use in treating diabetic wound complication.

[0058] In a preferred embodiment, the present disclosure relates to a composition comprising a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) for use in treating diabetic wound complication.

[0059] In an embodiment of the present disclosure, the diabetic wound complication is diabetic wound healing.

[0060] In an embodiment of the present disclosure, the subject is a mammal, including human being.

[0061] In an embodiment of the present disclosure, concentration of the peptide is in the range of about 0.01% - 2% and concentration of EGF is in the range of about 0.01% - 2%.

[0062] In an embodiment of the present disclosure, the composition optionally / further comprises excipients.

[0063] In an embodiment of the present disclosure, the excipients are present in the range of about 94% - 99.98%

[0064] In an embodiment of the present disclosure, the excipients are selected from a group comprising but not limited to preservatives, buffering agents, stabilizers, binders, lubricants, compaction agents, disintegration agents, dispersion agents, coloring agents, additive, solvent, surfactant, anti-oxidant, suspending agent, emulsifying agent or combinations thereof.

[0065] In an embodiment of the present disclosure, the composition is administered through modes such as but not limiting to intranasal, intravenous, intraperitoneal, intramuscular, sub-cutaneous, cutaneous, intradermal, oral, topical, cosmetic or combinations thereof. In an embodiment of the present invention, the composition is formulated into various forms selected from a group comprising but not limiting to drops, patches, nebulizers, injections, tablet, aerosols, atomized droplets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups, elixirs, cream, paste, spray, lotion, powder, ointment or combinations thereof.

[0066] In a preferred embodiment of the present disclosure, the composition is formulated into a topical / cosmetic composition.

[0067] In a preferred embodiment of the present disclosure, the composition is formulated into forms selected from a group comprising gel, cream, paste, spray, lotion, powder, ointment or combinations thereof.

[0068] In the present invention, EGF is combined with peptide formulations which significantly enhances wound healing efficacy in a diabetic wound model compared to peptide alone or EGF alone. The combined formulation promotes greater wound contraction, increased collagen production, and improved histopathological outcomes, including fibroblast proliferation, neovascularization, granulation tissue formation, and epithelialization. Specifically, the EGF and peptide combination exhibits a synergistic effect, resulting in superior wound closure and collagen formation. This suggests that EGF and peptide combinations offer a promising therapeutic strategy for improving wound healing, including diabetic wound complications. The study suggests that combining EGF with peptide is an optimal approach for promoting collagen formation and wound healing. Overall, the present study has implications for developing effective approaches for treating wounds, including diabetic wound care.

[0069] It is to be understood that the foregoing description is illustrative not a limitation. While considerable emphasis has been placed herein on particular features of this disclosure, it will be appreciated that various modifications can be made, and that many changes can be made in the preferred embodiments without departing from the principles of the disclosure. Those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein. Similarly, additional embodiments and features of the present disclosure will be apparent to one of ordinary skill in art based upon description provided herein.

[0070] Descriptions of well-known / conventional methods / steps and techniques are omitted so as to not unnecessarily obscure the embodiments herein. Further, the disclosure herein provides for examples illustrating the above-described embodiments, and in order to illustrate the embodiments of the present disclosure, certain aspects have been employed. The examples used herein for such illustration are intended merely to facilitate an understanding of ways in which the embodiments may be practiced and to further enable those of skill in the art to practice the embodiments. Accordingly, following examples should not be construed as limiting the scope of the embodiments herein.

[0071] Examples:

[0072] Example 1: Preparation of the composition

[0073] The present study was designed to evaluate the wound healing activity of the composition comprising the peptide of SEQ ID No. 1 and EGF. Peptide of SEQ ID No.l was synthesized and directly added at 0.1% to EGF at 0.015% along with excipients and mixed properly to obtain the composition. Similarly, peptide alone at 0.1% and EGF alone at 0.015% were prepared along with suitable excipients for conducting experiments.

[0074] The excipients used in the experiments are as follows:

[0075] Sodium carboxymethyl cellulose Sodium Chloride

[0076] Sodium Acetate

[0077] Glacial acetic acid

[0078] Methyl Paraben

[0079] Propyl Paraben m-Cresol

[0080] Lysine hydrochloride and

[0081] Deionized water

[0082] All the formulations were stored at 4°C throughout the duration of the study. Example 2: Animal Studies

[0083] Rats were fasted overnight in this experiment. Following overnight fasting, diabetes was induced in animals by intraperitoneal injections of 60 mg / kg Streptozotocin (STZ). They were allowed to drink 5% glucose solution overnight to overcome the drug-induced hypoglycemia. Rats were checked for fasting blood glucose using commercially available glucometer post 72 hr of induction to check diabetes induction (Blood glucose more than >250 mg / dl). Animals with successfully induced diabetes were selected and grouped for the study.

[0084] Three days post induction of diabetes, rats were anesthetized with intraperitoneal injection of ketamine (70 mg / kg) + xylazine (10 mg / kg) cocktail and the dorsal skin of animals was shaved using a pet trimmer. Depth of anesthesia was checked by tail pinch. A wound of about 2 cm x 2 cm was made on depilated dorsal thoracic region of animal. Under aseptic conditions, a pre -determined area of 2 cm x 2cm skin in its full thickness was excised using autoclaved surgical instruments under anesthesia. Post excision, 5mg / kg Ketoprofen was administered subcutaneously daily for two days to reduce the pain and stress. Following wound creation, animals were housed individually with species specific enrichments. On the day of wound creation, the wound area was measured by tracing the wound boundaries on a transparent paper. Animals were treated for 28 days post wound creation with reference and the composition of the present invention as specified in experimental design. Animals were treated topically daily for a period of twenty-eight days with EGF alone, peptide alone and the composition with EGF and peptide.

[0085] Animals were monitored for clinical signs, weekly body weight, morbidity and mortality. The efficacy parameters evaluated were body weights, clinical signs, percent wound contraction, collagen content in wound lysates by ELISA, and histopathology of skin for neovascularization, granulation tissue, fibroblast proliferation, epithelialization and collagen formation.

[0086] All animals found to be apparently normal until day 28. There was no significant loss in body weight through the study period. No clinical signs and mortality / morbidity were observed during the study.

[0087] Example 3: Percent Wound Contraction

[0088] Wound healing progression was monitored over a period of 28 days. Wound size was quantified and digital images of the wound area were captured at defined intervals such as Day 0, Day 7, Day 14, Day 21 and Day 28. The results are shown in Table 1 and Figures 1 & 2. It is clear from the results that the percent wound contraction in animals treated with the composition of EGF + peptide showed significant effect as compared to EGF and peptide alone.

[0089] Table 1: Percent Wound Contraction: Mean ± SD Note: ns - non significant;

[0090] Example 4: Collagen content in skin

[0091] Collagen content was measured in skin lysates using rat collagen ELISA kit. The concentration of collagen was normalized to total protein content using the Bradford method. The results are shown in

[0092] Table 2 and Figure 3. It is evident from the results that the collagen content in animals treated with the composition of EGF + peptide showed significant effect as compared to EGF and peptide alone respectively. Treatment with either EGF or peptide alone increased collagen concentrations (p < 0.001) compared to the control group. However, combining EGF with peptide yielded a synergistic effect, leading to an enhanced collagen production required for scarless wound healing.

[0093] Table 2: Collagen content in skin

[0094] Example 5: Histopathology

[0095] Skin samples collected on day 28 were processed and paraffin blocks prepared. Blocks were sectioned to 3 to 5 microns using rotatory microtome and mounted on clean glass slides. The slides were stained with Hematoxylin - Eosin (H&E) stain and observed under light microscope. Sections were assessed with respect to fibroblast proliferation, collagen formation, neovascularization, granulation tissue, and epithelialization using a 4-point scale as follows: 0=none, l=rare or minimal, 2=moderate, 3=abundant, and 4=severe or marked. For each specimen, three separate sections were selected randomly for histological evaluation.

[0096] Histological analysis parameters included were fibroblast proliferation, collagen formation, neovascularization, granulation tissue formation and epithelialization, (H&E Staining) scored on a 4-point scale. In the vehicle control group, minimal fibroblast proliferation, granulation tissue, and neovascularization were observed, indicating limited wound healing. The group with EGF + Peptide showed significant fibroblast proliferation, granulation tissue, and collagen formation compared to the control group as well as EGF and peptide alone [Table 3, Figure 4] thus indicating that the combination of EGF and peptide exhibits synergistic effect. Table 3: Histology scores after H&E staining: Mean ± SD

[0097] Note: ns - non significant;

Claims

We Claim:1) A composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF).2) The composition as claimed in claim 1, wherein concentration of the peptide is in the range of about 0.01% - 2% and concentration of the EGF is in the range of about 0.01% - 2%.3) The composition as claimed in claim 1, wherein the composition optionally comprises excipients in the range of about 94% - 99.98%.4) The composition as claimed in claim 1, wherein the excipients are selected from a group comprising preservatives, buffering agents, stabilizers, binders, lubricants, compaction agents, a disintegration agents, dispersion agents, coloring agents, additive, solvent, surfactant, anti-oxidant, suspending agent, emulsifying agent and combinations thereof.5) The composition as claimed in claim 1, wherein the composition is administered through modes selected from a group comprising intranasal, intravenous, intraperitoneal, intramuscular, sub-cutaneous, cutaneous, intradermal, oral, topical, cosmetic or combinations thereof.6) The composition as claimed in claim 1, wherein the composition is formulated into various forms selected from a group comprising drops, patches, nebulizers, injections, tablet, aerosols, atomized droplets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups, elixirs, cream, paste, spray, lotion, powder, ointment or combinations thereof.7) A composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 at a concentration ranging from about 0. 01 % - 2% and EGF at a concentration ranging from about 0.01% - 2%.8) A composition comprising a peptide of SEQ ID No. 1 at a concentration ranging from about 0.01% - 2% and EGF at a concentration ranging from about 0.01% - 2%.9) A process of preparing the composition, said process comprising step of combining a peptide having at least 90% homology to a peptide of SEQ ID No. 1 with epidermal growth factor (EGF).10) The process as claimed in claim 9, wherein the peptide is synthesized before combining with epidermal growth factor (EGF).11) The process as claimed in claim 9, wherein concentration of the peptide is in the range of about 0.01% - 2% and concentration of EGF is in the range of about 0.01% - 2%.12) The process as claimed in claim 9, wherein the process optionally comprise inclusion of excipients in the composition.13) The process as claimed in claim 9, wherein the excipients are in the range of about 94% - 99.98%.14) A method of treating wounds, said method comprising administering / applying an effective amount of a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) to a subject in need thereof.15) The method as claimed in claim 14, wherein the wounds are selected from a group comprising diabetic wound, bedsore, pressure ulcers, burns or combinations thereof.16) The method as claimed in claim 14, wherein the method results in a reduced scar or no scar [scarless wound healing] .17) A method of treating diabetic wound complication, said method comprising administering / applying an effective amount of a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) to a subject in need thereof.18) A composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) in manufacturing a medicament for treating wounds.19) The composition as claimed in claim 18, wherein the wounds are selected from a group comprising diabetic wound, bedsore, pressure ulcers, burns or combinations thereof.20) A composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF) in manufacturing a medicament for treating diabetic wound complication.

Images